Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Short-term Safety, Efficacy and Mode of Action of Apremilast in Moderate Suppurative Hidradenitis: A Randomised Double-blind Placebo Controlled Trial

NCT03049267 is registered in ClinicalTrials.gov with M.B.A. van Doorn as lead sponsor.

NCT NCT03049267
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03049267 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Short-term Safety, Efficacy and Mode of Action of Apremilast in Moderate Suppurative Hidradenitis: A Randomised Double-blind Placebo Controlled Trial
Lead sponsor
M.B.A. van Doorn
Phase
Phase 2
Overall status
Completed
Start date
February 2, 2017
Completion date
June 28, 2018
Enrollment
20 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hidradenitis suppurativa